Pharmacokinetics of methotrexate.

Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature (1980) 2.85

Effect of environmental factors on drug metabolism: decreased plasma half-life of antipyrine in workers exposed to chlorinated hydrocarbon insecticides. Clin Pharmacol Ther (1969) 2.75

Response of hepatic microbodies to a hypolipidemic agent, ethyl chlorophenoxyisobutyrate (CPIB). J Cell Biol (1966) 2.29

Impairment of antipyrine clearance in humans by propranolol. Circulation (1978) 2.18

Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion. Arch Gen Psychiatry (1999) 2.03

Drugs as etiologic factors in the Stevens-Johnson syndrome. Am J Med (1968) 1.98

Plasma protein binding of tricyclic anti-depressants in man. Biochem Pharmacol (1969) 1.86

Pharmacokinetics of tolbutamide: prediction by concentration in saliva. Clin Pharmacol Ther (1974) 1.69

The sick sinus syndrome. A study of 15 cases. Br Heart J (1972) 1.60

Pharmacokinetics of methotrexate. Clin Pharmacol Ther (1973) 1.55

Lack of benefit of very short basic drive train cycle length or repetition of extrastimulus coupling intervals for induction of ventricular tachycardia. J Cardiovasc Electrophysiol (1998) 1.38

Relationship between digoxin concentrations in serum and saliva. Clin Pharmacol Ther (1975) 1.38

The effect of spironolactone on antipyrine metabolism in man. Pharmacology (1973) 1.31

Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology (1993) 1.30

Correlation of the plasma elimination of antipyrine and the appearance of 4-hydroxy antipyrine in the urine of man. Biochem Pharmacol (1974) 1.28

Absorption of orally given digoxin preparations. JAMA (1972) 1.27

The effects of urine pH and plasma protein binding on the renal clearance of disopyramide. Clin Pharmacokinet (1977) 1.25

Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res (1974) 1.22

Nafenopin-induced hepatic microbody (peroxisome) proliferation and catalase synthesis in rats and mice. Absence of sex difference in response. J Cell Biol (1974) 1.21

Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther (1976) 1.14

Di-(2-ethylhexyl)phthalate: an industrial plasticizer induces hypolipidemia and enhances hepatic catalase and carnitine acetyltransferase activities in rat and mice. Life Sci (1976) 1.14

Long-term effects of clofibrate (Atromid-S) on serum lipids in man. Circulation (1969) 1.11

Theophylline bioavailability following chronic dosing of an elixir and two solid dosage forms. J Pharm Sci (1978) 1.09

Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14, 643), in rat and mouse liver. Cancer Res (1979) 1.09

Drugs and drug metabolites as environmental contaminants: chlorophenoxyisobutyrate and salicyclic acid in sewage water effluent. Life Sci (1977) 1.07

Clinical complications of corticosteroid therapy. A selected review. Med Clin North Am (1973) 1.06

Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism. N Engl J Med (1972) 1.04

Effect of in vivo elevation of free fatty acids on protein binding of drugs. Pharmacology (1974) 1.02

Tumors in male rats fed ethyl chlorophenoxyisobutyrate, a hypolipidemic drug. Cancer Res (1979) 1.00

The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin. Pharmacology (1972) 1.00

Correlation between plasma diphenhydramine level and sedative and antihistamine effects. Clin Pharmacol Ther (1978) 0.99

Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet (1978) 0.99

Pharmacokinetics, pharmacology of atenolol and effect of renal disease. Br J Clin Pharmacol (1979) 0.97

Prescription writing by generic name and drug cost. J Chronic Dis (1967) 0.96

Hepatic effects of some [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) analogs in the mouse. Arch Int Pharmacodyn Ther (1977) 0.95

A comparative study of drug metabolism in the isolated perfused liver and in vivo in rats. Eur J Pharmacol (1970) 0.95

Drug interactions with warfarin. Arch Intern Med (1968) 0.95

Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. J Pharmacol Exp Ther (1975) 0.94

Microbodies in experimentally altered cells. VI. Thyroxine displacement from plasma proteins and clofibrate effect. Arch Int Pharmacodyn Ther (1969) 0.93

Drug interactions. Pharmacol Physicians (1970) 0.93

Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest (1975) 0.92

Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans. Cancer Res (1974) 0.92

A rare cutaneous fungal infection complicating bacterial necrotising fasciitis. Hong Kong Med J (2008) 0.92

Drug protein binding and the nephrotic syndrome. Clin Pharmacokinet (1976) 0.92

Reversal of left ventricular remodeling by synchronous biventricular pacing in heart failure. Pacing Clin Electrophysiol (2000) 0.90

The effect of spironolactone and canrenone on the digoxin radioimmunoassay. Res Commun Chem Pathol Pharmacol (1974) 0.88

Daunorubicin metabolism in acute nonlymphocytic leukemia. Clin Pharmacol Ther (1973) 0.88

An epidemiological survey of blood pressures in Singapore. J Chronic Dis (1977) 0.88

Renal contribution to overall metabolism of drugs. II. Biotransformation of salicylic acid to salicyluric acid. J Pharm Sci (1972) 0.87

Induction of salicyluric acid formation in rheumatoid arthritis patients treated with salicylates. Clin Pharmacokinet (1983) 0.87

The effect of butoxamine on catecholamine-induced metabolic changes in humans. Clin Pharmacol Ther (1966) 0.87

Secretory activity and aryl acid content of serum, urine, and cerebrospinal fluid in normal and uremic man. J Lab Clin Med (1975) 0.87

Renal contribution to overall metabolism of drugs. 3. Metabolism of p-aminobenzoic acid. J Pharm Sci (1972) 0.87

Clofibrate effect on catecholamine-induced metabolic changes in humans. Metabolism (1968) 0.86

The instability of isoniazid and acetylisoniazid in frozen plasma. Res Commun Chem Pathol Pharmacol (1976) 0.86

Absorption and excretion of clindamycin-2-phosphate in children after intramuscular injection. Clin Pharmacol Ther (1972) 0.86

Hepatic peroxisome proliferation: induction by BR-931, a hypolipidemic analog of WY-14,643. Arch Int Pharmacodyn Ther (1978) 0.85

Association between clinical cardiac status, laboratory parameters, and digoxin usage. Am Heart J (1976) 0.85

Renal contribution to overall metabolism of drugs. I. Conversion of benzoic acid to hippuric acid. J Pharm Sci (1972) 0.85

Plasma levels and excretion of estrogens in urine in chronic lever disease. Gastroenterology (1975) 0.85

Absorption of digoxin from different oral preparations in normal subjects during steady state. Clin Pharmacol Ther (1974) 0.85

Disposition kinetics of disopyramide in patients with renal insufficiency. Biopharm Drug Dispos (1981) 0.84

Theophylline bioavailability: a comparison of the oral absorption of a theophylline elixir and two combination theophylline tablets to intravenous aminophylline. Am Rev Respir Dis (1977) 0.84

Renal contribution to overall metabolism of drugs. IV. Biotransformation of salicylic acid to salicyluric acid in man. J Pharm Sci (1973) 0.84

Effects of selected hypolipidemic drugs on cell ultrastructure. Fed Proc (1971) 0.83

Brugada syndrome. Hong Kong Med J (2013) 0.83

Bioavailability of aminosalicylic acid and its various salts in humans. 3. Absorption from tablets. J Pharm Sci (1974) 0.83

Diphenylhydantoin potency and plasma protein binding. J Pharmacol Exp Ther (1975) 0.83

GLC determination of atenolol and beta-blocking agents in biological fluids. J Pharm Sci (1978) 0.83

Metabolic disposition of antipyrine in patients with lung cancer. Cancer Res (1977) 0.82

1-methyl-4piperidyl-bis (P-chlorophenoxy) acetate: a new hypolipidemic peroxisome proliferator. Res Commun Chem Pathol Pharmacol (1975) 0.82

Metabolic responses to plasma concentrations of theophylline. Clin Pharmacol Ther (1979) 0.81

Topical application of lindane cream (Kwell) and antipyrine metabolism. J Invest Dermatol (1980) 0.81

Diphenylhydantoin: correlation between protein binding and albumin concentration. Klin Wochenschr (1975) 0.81

Pharmacology of hypolipidemic drugs. Introduction. Fed Proc (1971) 0.81

Quantitation of lidocaine and its deethylated metabolites in plasma and urine by gas chromatography-mass fragmentography. J Chromatogr (1978) 0.81

Kinetics, salivary excretion of amphetamine isomers, and effect of urinary pH. Clin Pharmacol Ther (1978) 0.81

A two-year crossover therapeutic trial with halofenate and clofibrate. Am J Med Sci (1977) 0.80

The interaction between halofenate and propranolol. Clin Pharmacol Ther (1976) 0.80

Pharmacokinetic investigations in elderly patients. Clinical and ethical considerations. Clin Pharmacokinet (1990) 0.80

Comparison of charcoal and attapulgite as gastrointestinal sequestrants in acute drug ingestions. Clin Toxicol (1971) 0.80

Bumetanide-induced rise in plasma renin activity. Clin Pharmacol Ther (1978) 0.80

Trigger thumbs in children: results of surgical release. Hong Kong Med J (2011) 0.80